IITF 2026 - EPFO Lounge & ESIC Pavilion inaugurated (See 'Corp Brief') Giriraj Singh visits Welspun World's State-of-the-Art Manufacturing Units in Kutch (See 'Corp Brief') PMLA - Status of secured creditor & initiation of prior recovery proceedings under SARFAESI Act do not exempt a property from attachment under PMLA, when property constitutes proceeds of crime: SAFEMA Tribunal (See 'Legal Desk') Indian Business leaders and Start ups to participate in the India-Egypt Business Forum (See 'Corp Brief') NRIDA selected for Medal for Innovation in Road Technology (See 'Corp Brief') PMLA - Objectives of special anti-money laundering law supersede private commercial security interests - properties linked to criminal activities liable to provisional & final attachment: SAFEMA Tribunal (See 'Legal Desk') Shilp Samagam Mela 2026 at Dilli Haat records Cumulative Sales of Over Rs 88.36 Lakh (See 'Corp Brief') National Tribal Literary Festival concludes with Emphasis on Preserving Oral Traditions (See 'Corp Brief') SEBI - Freezing the Appellants' demat & bank accounts pending deposit of alleged unlawful gains of Rs. 28.12 crore, is valid: SAT (See 'Legal Desk') MoS calls for strengthening India-Italy collaborative research for innovation (See 'Corp Brief') Ministry of Culture invites Partners to Build India's Creative Economy Together (See 'Corp Brief') DoT organises First All India Conference on Official Language 2026 in New Delhi (See 'Corp Brief') Centre strengthens healthcare network through 3 Urban Primary Health Centres (See 'Corp Brief') TDB-DST signs agreement with Astrome to develop sovereign space-based AI-ELINT constellation (See 'Corp Brief') 2nd Edition of the National Tribal Literary Festival 2026 begins in New Delhi (See 'Corp Brief') CCRAS-CARI and University of Delhi sign MoU to document medicinal plant diversity (See 'Corp Brief') RTI - Per Sections 2 & 3 of the Act, CPIO is not obligated to compile, analyze, correlate, or generate fresh datasets from disparate records in specific format desired by applicant: IBBI (See 'Legal Desk') Naturopathy Day 2026: Scientific Research strengthens India's Nature-Based Healthcare Ecosystem (See 'Corp Brief') India and Italy to deepen scientific cooperation through bilateral engagements (See 'Corp Brief') Yadav holds interaction with LeadIT Industry Members and Project Partners (See 'Corp Brief') SEBI - Stay on 5-year debarrment unwarranted where Appellant fails to make out prima facie case - unusual trading pattern noted along with admitted receipt of certain funds from connected entities: SAT (See 'Legal Desk') India strengthens Regional Health Partnerships as First BIMSTEC summit (See 'Corp Brief') CBN dismantles clan lab of mephedrone in Uttar Pradesh (See 'Corp Brief') IPR - Dominant element of composite mark is entitled to standalone protection and party cannot resile from concession made on court record without seeking formal recall of order: HC (See 'Legal Desk') An unsuccessful 'success fee' litigation (See CORP EINSICHT)

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES